Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Vistagen Therapeutics Inc. has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 examiner and 1 art unit, leaving the current prosecution activity concentrated in one examination setting. This profile supports a focused review of the office action, the cited art, and the examiner’s treatment of the claimed pharmaceutical subject matter.
HUI, SAN MING R is the busiest examiner, with 1 pending matter. The examiner therefore represents the entire identified workload. Counsel can direct prosecution planning through this single examiner relationship, with emphasis on a response that addresses the stated deficiencies without unnecessarily narrowing the claim set.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUI, SAN MING R | 1 | 59.6% | +20.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18611908 | DOSAGE FORMS AND THERAPEUTIC USES OF L-4-CHLOROKYNURENINE | HUI, SAN MING R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18611908 | DOSAGE FORMS AND THERAPEUTIC USES OF L-4-CHLOROKYNURENINE | HUI, SAN MING R | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18611908 | DOSAGE FORMS AND THERAPEUTIC USES OF L-4-CHLOROKYNURENINE | HUI, SAN MING R | 1627 | §101§103 | Non-Final OA | — | Pending | Mar 21, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVistagen Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
San Ming R Hui has the most, with 1 of Vistagen Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
